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found in the literature (min 22.90%, max 42.80%), treatment
with starting dose DA 500 mg Q3W resulted in a BI that were
35.64% and 27.64% lower than EPOalfa 10,000 UI TIW and
40,000 UI QW respectively and 35.59% and 17.11% lower than
EPObeta 10,000 UI TIW and 30,000 UI QW respectively. The
results of the base case did not change in any of the sensitivity
scenarios. CONCLUSION: The model shows that treatment of
CIA with starting dose DA 500 mg Q3W is the rapeutic strategy
with lower mean cost per patient for all the analyzed scenarios
in Spain.
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OBJECTIVE: Development of a decision analytic model to esti-
mate the budget impact on the Swedish health service of using a
more effective diagnostic tool in conjunction with white light
cystoscopy (WLC) in the management of superﬁcial bladder
cancer (SBC). Hexvix (hexaminolevulinate) ﬂuorescence cys-
toscopy potentially allows more complete detection and delin-
eation of tumours compared with WLC in bladder cancer
diagnosis. METHODS: Model inputs, including procedure costs
and clinical algorithms, are based on the bladder cancer diag-
nosis and treatment guidelines of the European Association of
Urology (EAU), literature review and Swedish clinical practice.
Several trials report less residual tumour at early re-resection fol-
lowing 5-ALA ﬂuorescence-assisted TURB with 59% to 80% rel-
ative reduction in recurrence in the ﬂuorescence group compared
to WLC. Based on these ﬁndings, the model assumed a conser-
vative 40% reduction in recurrence rate when Hexvix was used
alongside WLC to guide TURB. The model projects the ﬂow of
all newly diagnosed SBC patients, following histological risk
classiﬁcation at ﬁrst TURB, through treatment one year after
diagnosis. It covers Hexvix use in the operating room to guide
ﬁrst TURB in all patients with suspicion of bladder cancer and
all follow-up TURBs in patients with recurrent SBC. RESULTS:
In the Swedish population of newly diagnosed bladder cancer
patients, the model projects a reduction in the number of pro-
cedures required in the ﬁrst year compared to WLC alone, i.e.
29 cystectomies and 1961 TURBs with Hexvix compared to 52
and 2141 with WLC. Avoidance of these procedures would
result in $212,895 (SEK 1,561,908) reduction in costs to the
Swedish health service the ﬁrst year after diagnosis. CONCLU-
SIONS: The model predicts that use of Hexvix as an adjunct to
WLC for all initial and follow-up TURBs in the ﬁrst year fol-
lowing diagnosis will result in substantial cost savings for the
Swedish health service.
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OBJECTIVES: Primary (ﬁrst-cycle) prophylaxis with ﬁlgrastim
or second generation pegﬁlgrastim has been recommended in the
2006 ASCO and EORTC clinical guidelines when the risk of
febrile neutropenia (FN) is >20%. Recent studies reported sig-
niﬁcantly greater reduction of FN with pegﬁlgrastim than with
ﬁlgrastim, yet no study has compared their cost-effectiveness.
The study purpose was to evaluate the cost-effectiveness of
primary prophylaxis with pegﬁlgrastim versus 11-day use of ﬁl-
grastim (as recommended) in women with stage I-III breast
cancer receiving chemotherapy with moderate to high risk of FN
in Spain. METHODS: We constructed a decision-analytic model
from a health care payer’s perspective. Costs included costs for
drugs, drug administration, FN-related hospitalizations and sub-
sequent care, and were based on ex-factory price listing and 
literature. Effectiveness was measured as FN avoided and life-
years-gained (LYG). FN risk (varied by days of ﬁlgrastim), FN
case-fatality, relative dose intensity (RDI), and the impact of RDI
on survival were based on a comprehensive literature review and
expert panel validation. Breast cancer mortality and all-cause
mortality were from national cancer registries and vital statistics
report. Sensitivity analyses were conducted on key variables.
RESULTS: In addition to being more effective, pegﬁlgrastim
primary prophylaxis produced an average cost-savings of €32
per patient (€4243 pegﬁlgrastim versus €4275 ﬁlgrastim). Pegﬁl-
grastim reduced the absolute risk of FN by 5.5% (12.5% versus
7%) and had a LYG of 0.06 (16.48 versus 16.42 years). Age of
diagnosis and cancer stage had minimal impact on the results.
Key inﬂuencing factors included drug costs, relative risk of FN,
and drug administration cost. CONCLUSION: Primary pro-
phylaxis with pegﬁlgrastim in Spain appeared not only to be
more effective but also cost-saving compared with ﬁlgrastim used
for 11 days per cycle.
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In 2002, the medical services in Poland has been paid by the inde-
pendent public insurance institutions—Regional Cash of Ills. In
2003 the government established The National Fund of Health,
which integrate all regional insurance institutions and provide
identical availability of medical services for every patient in
Poland. OBJECTIVES: To assess the impact of changes in ﬁnanc-
ing of health services on costs structure from the payer perspec-
tives on the example of advanced ovarian cancer. METHODS:
Two regimens of chemotherapy were assessed: cisplatin-
cyclophospamide (CC) and cisplatin-paclitaxel (CP). The data of
medical resources consumed were collected retrospectively in
two oncology centers in Poland. All medical care consumption
(diagnostic tests, hospitalization, ambulatory care and medica-
tions) were estimated from the patients’ chart. Costs were
derived from the hospitals’ Financial Departments for the year
2002. And from the system used by National Fund of Health for
2006. All cost were in polish zloty. RESULTS: The total cost of
chemotherapy per patient in CP group in 2002 were 21,658 zl
and in 2006—14,594 zl, while the standard chemotherapy with
CC scheme were 9008 zl in 2002 and 6000 zl in 2006. In CP
group in 2002 the 72,5% of the total cost were the cost of cyto-
statics, while in 2006 they decreased to 52.2%. In CC group the
main costs (56%) in 2002 were additional medications such as
antiemetics and GCSF, while in 2006—51% of total costs was
the cost of hospitalization. CONCLUSIONS: The changes in
ﬁnancing of the health system decreased the total costs of ovarian
cancer chemotherapy. The main reason of it in PC group could
